Core Viewpoint - Stryker Corporation is expected to report its first-quarter 2025 results on May 1, with earnings estimated at $2.73 per share, reflecting a year-over-year increase of 9.2% and revenues projected at $5.70 billion, indicating an 8.8% growth from the previous year [1][2]. Group 1: Performance Drivers - The anticipated strong performance in the first quarter is attributed to robust sales in the U.S. market across various segments, including Instruments, Medical, Endoscopy, Trauma and Extremities, and Mako [3]. - The MedSurg and Neurotechnology segment experienced significant sales growth in the previous quarter, driven by the Surgical Technologies and orthopedic implants businesses, which is expected to continue [4]. - Recent product launches, including the next generation of SurgiCount+ and the Oculan Lighting Platform, are likely to contribute to additional sales in the first quarter [5]. Group 2: Product Portfolio and Acquisitions - The commercialization of the Pangea Plating system and strong sales of the LIFEPAK 35 defibrillator are expected to have positively impacted first-quarter results [6]. - New products like the Osteotomy Truss System and Ankle Truss System are anticipated to enhance the Foot & Ankle portfolio, improving surgical precision and patient outcomes [7]. - Stryker has completed five acquisitions in the latter half of 2024, which are expected to be accretive to quarterly results, enhancing its product offerings in various medical fields [8]. Group 3: Sales Estimates - Sales estimates for the MedSurg and Neurotechnology segments are projected at $3.75 billion, while Orthopaedics & Spine segments are estimated at $2.57 billion. U.S. sales are expected to be $4.74 billion, with international sales at $1.59 billion [9]. Group 4: Market Challenges - Ongoing challenges in China due to volume-based procurement policies and rising tariffs may partially offset international growth, although Stryker is addressing inflationary pressures and has recognized improved pricing and reduced cost pressures [10].

Core Viewpoint - DexCom, Inc. is set to release its first-quarter 2025 results on May 1, with expectations of revenue growth and potential challenges ahead [1][3][4]. Financial Performance - The Zacks Consensus Estimate for revenues is $1.02 billion, reflecting a 10.3% increase from the previous year [3]. - The consensus estimate for earnings is 33 cents per share, indicating a 3.1% year-over-year growth [3]. - In the last reported quarter, DexCom's earnings missed estimates by 10% but outperformed in three of the last four quarters, with an average surprise of 5.86% [1]. Market Dynamics - DexCom's performance is bolstered by an expanded U.S. prescriber base and improved coverage by major pharmacy benefit managers (PBMs) [5]. - The company has seen a record number of new patient starts and added 50,000 new clinicians in 2024, indicating strong commercial execution [6]. - U.S. revenues improved by 4% year-over-year in the fourth quarter, following a decline in the third quarter [7]. International Expansion - The international segment grew by 17% year-over-year in the last quarter, driven by the launch of G7 in Australia and coverage for Dexcom ONE+ in France and New Zealand [7][8]. - The return to growth in Japan, aided by a new sales structure, is a significant highlight [8]. Product Development - Stelo, an over-the-counter continuous glucose monitor, has gained traction with over 140,000 users in its first four months [8]. - DexCom plans to enhance Stelo's adoption through product iterations and partnerships, including integration with Oura Ring for comprehensive health monitoring [9]. Financial Outlook - DexCom projects full-year 2025 revenue of $4.6 billion, representing organic growth of 14% [10]. - The company anticipates continued margin improvement as it converts its installed base to G7 and scales manufacturing [10]. - DexCom holds a strong cash position of $2.58 billion, providing financial flexibility for strategic initiatives [11].

Core Viewpoint - Baxter International Inc. is expected to report first-quarter 2025 results on May 1, with a consensus estimate for revenues at $2.57 billion, reflecting a 28.4% decline year-over-year, and earnings per share (EPS) estimated at 48 cents, indicating a 26.2% year-over-year decline [1][2]. Revenue Estimates - The consensus estimate for total revenues is $2.57 billion, which represents a significant decline of 28.4% from the prior-year quarter [1]. - The model estimates total revenues from continuing operations to improve by 3.8% at constant currency to $2.58 billion [2]. Growth Factors - Baxter is likely to report moderate growth due to strong momentum in certain product lines, aided by easing macroeconomic pressures, with sales from continuing operations improving by 2% at constant currency in Q4 2024 [3]. - The company anticipates sales growth from continuing operations to be in the range of 3-4% [3]. Margin and Cost Considerations - Margins declined in the last reported quarter primarily due to one-time costs, including goodwill impairment charges and business optimization costs, which are expected to be reduced in the first quarter, potentially boosting the bottom line [4]. - The completion of a transformational plan, including the spin-off of certain business segments, is expected to enhance operational efficiency and improve EPS to a range of 47-50 cents [5]. Impact of Hurricane Helene - Baxter's recovery from Hurricane Helene has ensured minimal disruption in 2025, with all manufacturing lines restored to pre-hurricane levels, securing supply continuity [6]. - The Medical Products & Therapies segment is expected to have recovered from the hurricane's impact, aiding sales during the first quarter [7]. Segment Performance - Strong growth in infusion therapies, particularly the Novum IQ pump platform, is expected to continue, contributing positively to sales [8]. - The growth of parenteral nutrition products and Advanced Surgery products, along with recovery in IV solutions sales, is anticipated to drive segmental sales up by 6.6% at constant currency to $1.28 billion [9]. - The Healthcare Systems & Technologies segment may face challenges due to softness in the U.S. primary care market and delays in international capital spending, but patient support systems are expected to show resilience [10]. - The Pharmaceuticals segment is likely to improve, driven by a rebound in injectable drug sales and strong demand in drug compounding, with estimated sales growth of 14.4% at constant currency to $280.4 million [12][13].

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 展位有限 报名：首届全球心血管大会 | 奖项评选 报名：首届全球骨科大会 | 奖项评选 近日，许多医疗技术公司公布了第四季度财报信息和全年财报信息，其中有两条动态值得关注。 一是 碧迪医疗（Becton, Dickinson and Company） 宣布了一项战略决定， 将其生物科学和诊断部门从公司业务中分离出去。 该部门将成为一个独立的 公司，或者被出售给另一家公司。这样做的目的可能是为了专注于核心业务，提高运营效率，或者为股东释放价值。 二是 捷迈邦美（Zimmer Biomet） 宣布 以11亿美元的价格收购Paragon 28， 这 是一 家专注于骨科医疗设备的公司，这项收购利于扩大捷迈邦美产品 线，增强在骨科领域的竞争力，并可能通过整合资源和市场渠道来实现增长。 与此同时， Globus Medical 也公布了 以约2.5亿美元收购脊髓刺激公司Nevro的计划。 除去碧迪医疗、捷迈邦美之外，还有很多公司有类似的亮点决策，现思宇将其整理如下，供读者参考。 # 碧迪医疗 剥离生命科学业务，以加大对医疗科技领域的投资 公司首席执行官 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of in ...